Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study

Citation metadata

Date: Nov. 16, 2018
From: World Allergy Organization Journal(Vol. 11, Issue 1)
Publisher: BioMed Central Ltd.
Document Type: Report
Length: 6,351 words
Lexile Measure: 1480L

Document controls

Main content

Abstract :

Background Global chronic urticaria (CU) disease experience and management is not well documented. This study descriptively compares these aspects among CU patients residing in Europe (EU) and Central and South America (C/SA). Methods AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is a global prospective, non-interventional study of CU in the real-world setting. Patients were [greater than or equai to] 18 years with a diagnosis of H1-antihistamine-refractory CU for 2 months. Differences between the EU and C/SA regions in demographic and clinical characteristics, quality of life (QoL), work and activity impairment, pharmacological treatment, and healthcare resource use were examined. Results In total, 4224 patients were included in the analysis (C/SA 492; EU 3732). Rates of untreated patients were greater in the C/SA region (45.1% vs. 31.9%; P Conclusions This study revealed that CU is a heterogeneous condition with differences in healthcare utilization and outcomes between EU and C/SA. However, overall there is a high unmet need of H1-antihistamine-refractory CU patients, which is associated with high use of healthcare resources, and has a large negative effect on QoL and work productivity. Keywords: Angioedema, Chronic spontaneous urticaria, Quality of life, Urticaria

Source Citation

Source Citation   

Gale Document Number: GALE|A568040321